Citigroup’s KALA BIO KALA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-232
Closed -$6.45K 6174
2025
Q4
$6.45K Buy
232
+218
+1,557% +$9.76K ﹤0.01% 5177
2025
Q3
$1.1K Buy
+14
New +$6.94K ﹤0.01% 5609
2025
Q1
Sell
-114
Closed -$39.4K 5778
2024
Q4
$39.4K Buy
114
+108
+1,800% +$34K ﹤0.01% 5141
2024
Q3
$1.69K Hold
6
﹤0.01% 5423
2024
Q2
$2.1K Hold
6
﹤0.01% 5331
2024
Q1
$2.32K Hold
6
﹤0.01% 5379
2023
Q4
$2.07K Hold
6
﹤0.01% 5413
2023
Q3
$2.63K Hold
6
﹤0.01% 4891
2023
Q2
$4.32K Hold
6
﹤0.01% 5202
2023
Q1
$4.46K Sell
6
-4
-40% -$3.49K ﹤0.01% 4971
2022
Q4
$18.1K Buy
10
+4
+67% +$1.58K ﹤0.01% 4633
2022
Q3
$3K Hold
6
﹤0.01% 5390
2022
Q2
$5K Sell
6
-3
-33% -$4.71K ﹤0.01% 5617
2022
Q1
$33K Sell
9
-3
-25% -$7.86K ﹤0.01% 4911
2021
Q4
$36K Buy
12
+7
+140% +$32.5K ﹤0.01% 5211
2021
Q3
$31K Buy
5
+1
+25% +$8.63K ﹤0.01% 5009
2021
Q2
$47K Sell
4
-4
-50% -$62.9K ﹤0.01% 4858
2021
Q1
$140K Buy
8
+3
+60% +$58.6K ﹤0.01% 4211
2020
Q4
$79K Hold
5
﹤0.01% 5723
2020
Q3
$92K Sell
5
-170
-97% -$3.91M ﹤0.01% 5179
2020
Q2
$4.59M Buy
175
+172
+5,733% +$4.87M ﹤0.01% 1940
2020
Q1
$70K Hold
3
﹤0.01% 5663
2019
Q4
$27K Buy
3
+2
+200% +$19.3K ﹤0.01% 6774
2019
Q3
$9K Sell
1
-2
-67% -$24.3K ﹤0.01% 7123
2019
Q2
$42K Buy
3
+1
+50% +$16.6K ﹤0.01% 6625
2019
Q1
$40K Buy
2
+1
+100% +$17.8K ﹤0.01% 6512
2018
Q4
$17K Hold
1
﹤0.01% 6953
2018
Q3
$25K Buy
+1
New +$30.5K ﹤0.01% 6974
2018
Q2
Sell
-1
Closed -$38.4K 7049
2018
Q1
$51K Hold
1
﹤0.01% 6156
2017
Q4
$30K Sell
1
-23
-96% -$1.08M ﹤0.01% 6505
2017
Q3
$1.35M Buy
+24
New +$1.32M ﹤0.01% 3060

Other funds holding KALA

Citigroup's KALA Position: Q1 2026 in Review

Citigroup sold out of KALA BIO (KALA) in Q1 2026, closing a stake of 232 shares — an estimated $6.45K sold.

Citigroup first reported a position in KALA in Q3 2017 and held it in 31 quarters. The position peaked at $4.59M in Q2 2020. 28 funds tracked by Wall St. Rank hold KALA as of Q1 2026.

  • Citigroup reported no remaining KALA BIO position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 232 KALA BIO shares in Q1 2026, an estimated $6.45K.
  • Citigroup first reported a position in KALA BIO in Q3 2017 and held it in 31 quarters.
  • Citigroup's KALA BIO position peaked at $4.59M in Q2 2020.
  • 28 funds tracked by Wall St. Rank held KALA BIO as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.